Literature DB >> 22274916

Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia.

Umran Kucukgoz Gulec1, Semra Paydas, Ahmet Baris Guzel, Selim Buyukkurt, Gulsah Seydaoglu, Mehmet Ali Vardar.   

Abstract

The aim of this study was to investigate the diagnostic role of the CA 125, ferritin, beta-2 microglobulin (β2 M), and lactic dehydrogenase (LDH) levels in serum and peritoneal fluid (PF) in patients with ovarian neoplasms. Using cross-sectional study design; serum and PF CA 125, ferritin, β2 M, and LDH levels were analyzed in 40 patients with benign ovarian neoplasms (Group 1) and 59 patients with malignant ovarian neoplasms (Group 2) which were evaluated surgically. Serum and PF levels of these markers compared between the groups. Diagnostic role of these markers were determined with receiver operating curve (ROC) analysis. Serum and PF CA 125, ferritin, β2 M, and LDH levels were statistically significant higher in patients with ovarian cancers as compared with benign neoplasms. Among these biomarkers, PF β2 M levels had highest sensitivity and specificity, 76.3 and 85%, respectively with the cut-off value: 2.3 mg/l. This study results indicates that especially PF β2 M and ferritin levels may be valuable for diagnosis of malignant ascites in patients with ovarian neoplasms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22274916     DOI: 10.1007/s12032-012-0165-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  23 in total

Review 1.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

2.  Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids.

Authors:  A Sevinc; S Buyukberber; R Sari; Y Kiroglu; H M Turk; M Ates
Journal:  Gynecol Oncol       Date:  2000-05       Impact factor: 5.482

3.  Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer.

Authors:  K Yüce; C Baykal; C Genç; A Al; A Ayhan
Journal:  Eur J Gynaecol Oncol       Date:  2001       Impact factor: 0.196

4.  Diagnostic value of ferritin in the differential diagnosis of malignant effusions.

Authors:  A Demirkazik; D Dinçol; S Hastürk; A Arican; H Karaoguz; F Cay; F Içli
Journal:  Cancer Biochem Biophys       Date:  1998-10

5.  Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer.

Authors:  Phil Rolland; Suha Deen; Ian Scott; Lindy Durrant; Ian Spendlove
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

6.  Potential markers that complement expression of CA125 in epithelial ovarian cancer.

Authors:  Daniel G Rosen; Lin Wang; J Neeley Atkinson; Yinhua Yu; Karen H Lu; Eleftherios P Diamandis; Ingegerd Hellstrom; Samuel C Mok; Jinsong Liu; Robert C Bast
Journal:  Gynecol Oncol       Date:  2005-08-02       Impact factor: 5.482

Review 7.  Analysis of HLA expression in human tumor tissues.

Authors:  Teresa Cabrera; Miguel Angel López-Nevot; Jose Juan Gaforio; Francisco Ruiz-Cabello; Federico Garrido
Journal:  Cancer Immunol Immunother       Date:  2002-12-10       Impact factor: 6.968

8.  Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125.

Authors:  A G Zeimet; C Marth; F A Offner; P Obrist; M Uhl-Steidl; H Feichtinger; S Stadlmann; G Daxenbichler; O Dapunt
Journal:  Gynecol Oncol       Date:  1996-09       Impact factor: 5.482

9.  Correlation of tumour markers in ascitic fluid and serum: are measurements of ascitic tumour markers a futile attempt?

Authors:  Y Tuzun; Y Celik; K Bayan; S Yilmaz; M Dursun; F Canoruc
Journal:  J Int Med Res       Date:  2009 Jan-Feb       Impact factor: 1.671

10.  Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms.

Authors:  S E Kabawat; R C Bast; W R Welch; R C Knapp; A K Bhan
Journal:  Int J Cancer       Date:  1983-11-15       Impact factor: 7.396

View more
  4 in total

Review 1.  Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.

Authors:  Khalid El Bairi; Abdul Hafeez Kandhro; Adel Gouri; Wafaa Mahfoud; Noureddine Louanjli; Brahim Saadani; Said Afqir; Mariam Amrani
Journal:  Cell Oncol (Dordr)       Date:  2016-12-15       Impact factor: 6.730

2.  Low expression of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in non-Hodgkin lymphoma and a significant correlation with β2-microglobulin.

Authors:  Dongbing Ding; Wenbin Chen; Changfu Zhang; Zhe Chen; Yanmei Jiang; Ziyi Yang; Xudong Jiang; Yunfei Zuo; Shuangyi Ren
Journal:  Med Oncol       Date:  2014-09-03       Impact factor: 3.064

3.  Human epithelial-type ovarian tumour marker beta-2-microglobulin is regulated by the TGF-β signaling pathway.

Authors:  Wenwen Sun; Lu Gui; Xulei Zuo; Lingyun Zhang; Daibing Zhou; Xiaoling Duan; Weimin Ren; Guoxiong Xu
Journal:  J Transl Med       Date:  2016-03-16       Impact factor: 5.531

4.  HE4 tumor marker concentration in neoplastic peritoneal effusion and in peritoneal fluid associated with benign gynecological diseases.

Authors:  Anita Chudecka-Głaz; Aneta Cymbaluk-Płoska; Janusz Menkiszak; Agnieszka Sompolska-Rzechuła; Elżbieta Byra; Izabella Rzepka-Górska
Journal:  J Ovarian Res       Date:  2014-02-14       Impact factor: 4.234

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.